The number of cancer stem cell contribute BCG resistance of the urinaly CIS

• Project/Area Number: 26861289
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Urology
• Research Institution: Nara Medical University
• Principal Investigator: Inoue Takeshi 奈良県立医科大学, 医学部, 助教 (30719539)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000); Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
• Keywords: 膀胱癌 / 上皮内癌 / がん幹細胞 / DNAメチル化 / 膀胱上皮内癌 / BCG / 上皮間葉転換

Outline of Final Research Achievements

The purpose of this study is to establish the molecular markers which enables to
diagnose the BCG resistant CIS of the bladder, that is focused on cancer stem cell markers or EMT markers. Our in vitro study revealed the number of stem cell marker positive cells prescribed the BCG resistance. On the other hands, in vivo study, we could not find the correlations between BCG resistance and the number of cells which were positive for stem cell markers. However, DNA methylation level of the stem cell genes were significantly low in the BCG resistant cases. These result showed that DNA methylation regulate the expression of stem cell genes.